Pyxis Oncology’s (PYXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note released on Friday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock, down from their prior price target of $7.00.

A number of other research analysts have also commented on PYXS. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Stephens began coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a report on Friday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.69 on Friday. The stock has a 50-day simple moving average of $2.93 and a 200 day simple moving average of $3.29. Pyxis Oncology has a twelve month low of $1.49 and a twelve month high of $6.85. The stock has a market capitalization of $100.50 million, a PE ratio of -1.64 and a beta of 1.00.

Insider Activity

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the acquisition, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently modified their holdings of the stock. Fullcircle Wealth LLC bought a new stake in Pyxis Oncology in the second quarter valued at $40,000. Intech Investment Management LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter worth about $55,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $58,000. The Manufacturers Life Insurance Company bought a new position in Pyxis Oncology during the 2nd quarter valued at about $65,000. Finally, MetLife Investment Management LLC boosted its position in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.